Autopsy report · NCT03519308

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

“The accrual goal could not be met and the drug manufacturer pulled support”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 3 months before it started.
• Ran for about 1 year 9 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Abramson Cancer Center at Penn Medicine

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

Nivolumab; Nab-Paclitaxel; Gemcitabine; Paricalcitol

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (66% match in meaning)
• Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes
  “Drug no longer being supplied by sponsor” (63% match in meaning)
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
  “Pharmaceutical company pulled support for the trial.” (61% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (61% match in meaning)
• Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma
  “Terminated 4/17/07. Drug sponsor withdrew.” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.